MRNA Polyplexes with Post-Conjugated GALA Peptides Efficiently Target, Transfect, and Activate Antigen Presenting Cells
Overview
Affiliations
Vaccines based on mRNA have emerged as potent systems to elicit CD8 T cell responses against various cancers and viral infectious diseases. The efficient intracellular delivery of mRNA molecules encoding antigens into the cytosol of antigen-presenting cells (APCs) is still challenging, requiring cell attachment, active uptake, and subsequent endosomal escape. Here, we report a facile approach for the formulation of peptide-functionalized mRNA polyplexes using copper-free click chemistry to promote presentation of mRNA antigen by dendritic cells (DCs). After screening different membrane active peptides, GALA modified mRNA polyplexes (PPx-GALA) with a size around 350 nm and with a slightly negative surface charge (-7 mV), exhibited the highest EGFP-mRNA transfection in RAW 246.7 macrophages (∼36%) and D1 dendritic cells (∼50%) as compared to polyplexes decorated with melittin or LEDE peptides. Interestingly, we found that PPx-GALA enters DCs through sialic acid mediated endo/phagocytosis, which was not influenced by DC maturation. The PPx-GALA formulation exhibited 18-fold higher cellular uptake compared to a lipofectamine mRNA formulation without inducing cytotoxicity. Live cell imaging showed that PPx-GALA that were taken up by endocytosis induced calcein release from endosomes into the cytosol. DCs treated with PPx-GALA containing mRNA encoding for OVA displayed enhanced T cell responses and DC maturation. Collectively, these data provide a strong rationale for further study of this PPx-GALA formulation in vivo as a promising mRNA vaccine platform.
Advances and prospects of RNA delivery nanoplatforms for cancer therapy.
Attia M, Kijanka G, Nguyen N, Zhang J, An H Acta Pharm Sin B. 2025; 15(1):52-96.
PMID: 40041887 PMC: 11873661. DOI: 10.1016/j.apsb.2024.09.009.
Tuning the tropism and infectivity of SARS-CoV-2 virus-like particles for mRNA delivery.
Yang Q, Davidson B, Pajic P, Chen X, Gokcumen O, Gao M Nucleic Acids Res. 2025; 53(5).
PMID: 40037714 PMC: 11879429. DOI: 10.1093/nar/gkaf133.
Respiratory delivered vaccines: Current status and perspectives in rational formulation design.
Wu L, Xu W, Jiang H, Yang M, Cun D Acta Pharm Sin B. 2025; 14(12):5132-5160.
PMID: 39807330 PMC: 11725141. DOI: 10.1016/j.apsb.2024.08.026.
Haghighi E, Abolmaali S, Dehshahri A, Mousavi Shaegh S, Azarpira N, Tamaddon A J Nanobiotechnology. 2024; 22(1):710.
PMID: 39543630 PMC: 11566655. DOI: 10.1186/s12951-024-02972-w.
Lipid Nanoparticle-Based Delivery System-A Competing Place for mRNA Vaccines.
Zhang X, Li Y, Zhou Z ACS Omega. 2024; 9(6):6219-6234.
PMID: 38371811 PMC: 10870384. DOI: 10.1021/acsomega.3c08353.